{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:25:26Z","timestamp":1775316326735,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011957","name":"Takeda Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40271-018-0352-2","type":"journal-article","created":{"date-parts":[[2018,12,16]],"date-time":"2018-12-16T20:12:31Z","timestamp":1544991151000},"page":"339-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Elicitation of Health-Related Utility in Perianal Fistula in Crohn\u2019s Disease"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-4862","authenticated-orcid":false,"given":"Louise","family":"Longworth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Fountain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeshika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Azzabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glynn","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Lundstam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"issue":"9","key":"352_CR1","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1046\/j.1365-2036.2003.01561.x","volume":"17","author":"SJ Bell","year":"2003","unstructured":"Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn\u2019s disease. Aliment Pharmacol Ther. 2003;17(9):1145\u201351.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"352_CR2","first-page":"299","volume":"53","author":"G Sciaudone","year":"2010","unstructured":"Sciaudone G, Di Stazio C, Limongelli P, Guadagni I, Pellino G, Riegler G, et al. Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach. Can J Surg. 2010;53(5):299\u2013304.","journal-title":"Can J Surg"},{"issue":"9","key":"352_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/apt.14599","volume":"47","author":"PF Vollebregt","year":"2018","unstructured":"Vollebregt PF, van Bodegraven AA, Markus-de Kwaadsteniet TML, van der Horst D, Felt-Bersma RJF. Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47(9):1253\u201360.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"352_CR4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3748\/wjg.v21.i5.1394","volume":"21","author":"M Marzo","year":"2015","unstructured":"Marzo M, Felice C, Pugliese D, Andrisani G, Mocci G, Armuzzi A, et al. Management of perianal fistulas in Crohn\u2019s disease: an up-to-date review. World J Gastroenterol. 2015;21(5):1394\u2013403.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"352_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/MPG.0b013e3182a025ee","volume":"57","author":"EF Zoeten de","year":"2013","unstructured":"de Zoeten EF, Pasternak BA, Mattei P, Kramer RE, Kader HA. Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement. J Pediatr Gastroenterol Nutr. 2013;57(3):401\u201312.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"Suppl 4","key":"352_CR6","doi-asserted-by":"crossref","first-page":"iv2","DOI":"10.1136\/gut.49.suppl_4.iv2","volume":"49","author":"M Falconi","year":"2001","unstructured":"Falconi M, Pederzoli P. The relevance of gastrointestinal fistulae in clinical practice: a review. Gut. 2001;49(Suppl 4):iv2\u201310.","journal-title":"Gut"},{"issue":"10","key":"352_CR7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00384-014-1935-6","volume":"29","author":"G Maconi","year":"2014","unstructured":"Maconi G, Gridavilla D, Vigano C, Sciurti R, Asthana AK, Furfaro F, et al. Perianal disease is associated with psychiatric co-morbidity in Crohn\u2019s disease in remission. Int J Colorectal Dis. 2014;29(10):1285\u201390.","journal-title":"Int J Colorectal Dis"},{"issue":"5","key":"352_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/DCR.0b013e3182099d9e","volume":"54","author":"S Mahadev","year":"2011","unstructured":"Mahadev S, Young JM, Selby W, Solomon MJ. Quality of life in perianal Crohn\u2019s disease: what do patients consider important? Dis Colon Rectum. 2011;54(5):579\u201385.","journal-title":"Dis Colon Rectum"},{"issue":"12","key":"352_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.dld.2015.08.001","volume":"47","author":"A Grouin","year":"2015","unstructured":"Grouin A, Brochard C, Siproudhis L, Leveque J, Bretagne J-F, Poulain P, et al. Perianal Crohn\u2019s disease results in fewer pregnancies but is not exacerbated by vaginal delivery. Dig Liver Dis. 2015;47(12):1021\u20136.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"352_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"key":"352_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-1-54","volume":"1","author":"J Horsman","year":"2003","unstructured":"Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.","journal-title":"Health Qual Life Outcomes"},{"key":"352_CR12","unstructured":"NICE. Guide to the methods of technology appraisal. 2013. https:\/\/www.nice.org.uk\/article\/pmg9\/chapter\/Foreword . Accessed 12 Dec 2018."},{"issue":"1","key":"352_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jval.2010.10.015","volume":"14","author":"JC Tosh","year":"2011","unstructured":"Tosh JC, Longworth LJ, George E. Utility values in National Institute for Health and Clinical Excellence (NICE) technology appraisals. Value Health. 2011;14(1):102\u20139.","journal-title":"Value Health"},{"issue":"1","key":"352_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jval.2012.10.010","volume":"16","author":"L Longworth","year":"2013","unstructured":"Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202\u201310.","journal-title":"Value Health"},{"issue":"7","key":"352_CR15","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1053\/gast.2001.24884","volume":"120","author":"KO Arseneau","year":"2001","unstructured":"Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn\u2019s disease perianal fistulae. Gastroenterology. 2001;120(7):1640\u201356.","journal-title":"Gastroenterology"},{"issue":"3","key":"352_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1524-4733.2007.00171.x","volume":"10","author":"MJ Buxton","year":"2007","unstructured":"Buxton MJ, Lacey LA, Feagan BG, Niecko T, Miller DW, Townsend RJ. Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn\u2019s Disease Activity Index in Crohn\u2019s disease and measures of utility. Value Health. 2007;10(3):214\u201320.","journal-title":"Value Health"},{"issue":"4","key":"352_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jval.2014.04.002","volume":"17","author":"M Oppe","year":"2014","unstructured":"Oppe M, Devlin NJ, van Hout B, Krabbe PFM, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health. 2014;17(4):445\u201353.","journal-title":"Value Health."},{"issue":"10","key":"352_CR18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-016-0404-1","volume":"34","author":"M Oppe","year":"2016","unstructured":"Oppe M, Rand-Hendriksen K, Shah K, Ramos-Goni JM, Luo N. EuroQol protocols for time trade-off valuation of health outcomes. Pharmacoeconomics. 2016;34(10):993\u20131004.","journal-title":"Pharmacoeconomics."},{"issue":"Suppl 1","key":"352_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10198-013-0502-3","volume":"14","author":"NJ Devlin","year":"2013","unstructured":"Devlin NJ, Krabbe PFM. The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ. 2013;14(Suppl 1):1\u20133.","journal-title":"Eur J Health Econ."},{"issue":"Suppl 1","key":"352_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10198-013-0503-2","volume":"14","author":"BMF Janssen","year":"2013","unstructured":"Janssen BMF, Oppe M, Versteegh MM, Stolk EA. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ. 2013;14(Suppl 1):5\u201313.","journal-title":"Eur J Health Econ."},{"issue":"1","key":"352_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","volume":"27","author":"NJ Devlin","year":"2018","unstructured":"Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7\u201322.","journal-title":"Health Econ."},{"key":"352_CR22","unstructured":"Office for National Statistics. 2011 census data. 2011. https:\/\/www.ons.gov.uk\/census\/2011census\/2011censusdata ."},{"key":"352_CR23","unstructured":"NHS Digital. Adult Dental Health Survey. 2009. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/adult-dental-health-survey\/adult-dental-health-survey-2009-summary-report-and-thematic-series . Accessed 12 Dec 2018."},{"issue":"4","key":"352_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2165\/00148365-200504040-00002","volume":"4","author":"J Brazier","year":"2005","unstructured":"Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, et al. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy. 2005;4(4):201\u20138.","journal-title":"Appl Health Econ Health Policy."},{"issue":"4","key":"352_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/14737167.2016.1190644","volume":"16","author":"KP Malinowski","year":"2016","unstructured":"Malinowski KP, Kawalec P. Health utility of patients with Crohn\u2019s disease and ulcerative colitis: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):441\u201353.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"9","key":"352_CR26","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/000313481207800934","volume":"78","author":"A Grucela","year":"2012","unstructured":"Grucela A, Gurland B, Kiran RP. Functional outcomes and quality of life after anorectal surgery. Am Surg. 2012;78(9):952\u20136.","journal-title":"Am Surg."},{"issue":"2","key":"352_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/hec.1580","volume":"19","author":"J Brazier","year":"2010","unstructured":"Brazier J, Tsuchiya A. Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ. 2010;19(2):125\u20139.","journal-title":"Health Econ."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-018-0352-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-018-0352-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-018-0352-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T14:38:53Z","timestamp":1775313533000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-018-0352-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,17]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1007\/s40271-018-0352-2","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,17]]},"assertion":[{"value":"17 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This research and preparation of the manuscript was funded by Takeda Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ismail Azzabi and Glynn Owen were employees at Takeda when this study was conducted. Shaji Sebastian has received grants and consulting fees from Takeda. Ulf Lundstarm has received consultancy fees from Takeda. Louise Longworth, Donna Fountain and Jeshika Singh declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data subject to third-party restriction. The data that support the findings of this study are available from Takeda Pharmaceuticals but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of Takeda Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}